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Background: Hypoxic–ischemic encephalopathy following perinatal asphyxia is a lead-
ing cause of neonatal death and disability worldwide. Treatment with therapeutic hypo-
thermia reduced adverse outcomes from 60 to 45%. Additional strategies are urgently 
needed to further improve the outcome for these neonates. Inhibition of nitric oxide 
synthase (NOS) is a potential neuroprotective target. This article reviews the evidence of 
neuroprotection by nitric oxide (NO) synthesis inhibition in animal models.
Methods: Literature search using the EMBASE, Medline, Cochrane, and PubMed 
databases. Studies comparing NOS inhibition to placebo, with neuroprotective outcome 
measures, in relevant animal models were included. Methodologic quality of the included 
studies was assessed.
Results: 26 studies were included using non-selective or selective NOS inhibition in rat, 
piglet, sheep, or rabbit animal models. A large variety in outcome measures was reported. 
Outcome measures were grouped as histological, biological, or neurobehavioral. Both 
non-selective and selective inhibitors show neuroprotective properties in one or more 
outcome measures. Methodologic quality was either low or moderate for all studies.
Conclusion: Inhibition of NO synthesis is a promising strategy for additional neuropro-
tection. In humans, intervention can only take place after the onset of the hypoxic–isch-
emic event. Therefore, combined inhibition of neuronal and inducible NOS seems the 
most likely candidate for human clinical trials. Future studies should determine its safety 
and effectiveness in neonates, as well as a potential sex-specific neuroprotective effect. 
Researchers should strive to improve methodologic quality of animal intervention studies 
by using a systematic approach in conducting and reporting of these studies.
Keywords: nitric oxide synthase inhibition, neuroprotection, animal models, hypoxic–ischemic encephalopathy, 
2-iminobiotin, review
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inTRODUCTiOn
Hypoxic–ischemic encephalopathy (HIE) following perinatal 
asphyxia (i.e., severe oxygen deprivation at birth) is one of the 
leading causes of neonatal death and adverse neuromotor out-
come in term and near-term infants worldwide. In high-income 
countries, the incidence of HIE has been estimated between 0.5 
and 1.0 for every thousand live births, although some sources 
have reported an incidence as high as 8 per 1,000 live births (1, 
2). In low- and middle-income countries, the incidence of HIE 
is higher, affecting more than 1.1 million babies annually (3–5).
The overall burden of HIE is high, in terms of quality-adjusted 
life years, years of life lost, and years lived with disability, not to 
mention a great financial cost for both society and the families 
involved (6, 7). With an estimated annual one million deaths 
worldwide, HIE is accountable for roughly 25% of all deaths in 
the neonatal period (3, 8).
Hypoxic–ischemic brain injury is not a single event, evoked by 
the actual asphyxia, but rather an ongoing process that leads to sig-
nificant neuronal cell death over hours to days after the initial insult 
(9, 10). Several distinct phases have been identified in this process. 
The primary energy failure takes place during the hypoxic–ischemic 
event, resulting in failure of oxidative metabolism, cytotoxic edema, 
and accumulation of excitotoxins (11). After resuscitation and 
restoration of cerebral circulation, a latent phase, lasting approxi-
mately 6 h, commences (12, 13). Subsequently, starting between 6 
and 15 h after asphyxia, the brain experiences a secondary energy 
failure that can last for days. This phase is marked by seizures, 
renewed cytotoxic edema, release of excitotoxins, impaired cerebral 
oxidative energy metabolism, and finally, neuronal cell death (14).
Currently, the only treatment that has proven to effectively 
reduce hypoxic–ischemic brain injury following perinatal 
asphyxia is the application of therapeutic hypothermia (TH). 
During TH the brain temperature is lowered to 33–34°C which 
is maintained for 72  h (1). Since the introduction of TH, the 
combined adverse outcome of death and disability, such as 
hearing loss, cerebral palsy, and other neuromotor disorders, 
has been reduced from approximately 60–45% (15–17). TH has 
widely been implemented as the standard of care treatment for 
moderate to severe HIE in high-income countries. However, TH 
needs to be started within 6 h after birth, leaving clinicians with a 
narrow window for establishing the diagnosis and severity of HIE 
as well as transportation to a medical facility equipped for TH 
(18). Additional neuroprotective strategies for HIE are urgently 
needed to augment TH, but when hypothermia is not yet feasible, 
act as a first line treatment option (3, 4, 19).
A potential target for (additional) neuroprotection in patients 
with HIE is the inhibition of nitric oxide synthase (NOS, enzyme 
commission number 1.14.13.39). NOS is an enzyme catalyzing 
production of nitric oxide (NO) from l-arginine. After perinatal 
asphyxia, NO can react with the superoxide free radical to form 
toxic peroxynitrite, setting a pre-apoptotic pathway in motion, 
resulting in neuronal loss (10, 20). Nitrotyrosine, an end product 
of this process, has been demonstrated post mortem in neonatal 
brain and spinal cord tissue after severe HIE (21, 22).
Three isoforms of NOS have been identified: endothelial (eNOS), 
neuronal (nNOS), and inducible NOS (iNOS) (23). All isoforms 
are upregulated after asphyxia; both nNOS and eNOS immediately 
after reperfusion and iNOS from several hours onward (24). While 
eNOS is regarded to be critical in maintaining pulmonary blood 
flow, preventing pulmonary hypertension and thereby maintaining 
adequate oxygenation of tissues throughout the body, excessive 
activation of nNOS and iNOS is associated with deleterious effects 
on the brain (24, 25). To illustrate, in mice genetically deficient of 
eNOS, infarct size after middle cerebral artery occlusion is larger 
compared with wild-type animals, due to a reduction in regional 
cerebral blood flow (26). By contrast, nNOS knockout mice are 
protected against hypoxic–ischemic brain injury, while mice lack-
ing iNOS showed a delayed reduction in brain injury (27–32).
The aim of this study is to review the available evidence on 
NOS inhibition as a potential neuroprotective strategy in animal 
models translational for neonatal HIE and to identify one or more 
NOS inhibiting compounds that could evolve from preclinical to 
clinical studies in the near future.
MeTHODS
Search Strategy
Studies assessing the neuroprotective effects of NOS inhibi-
tors in HIE models were identified. A literature search using 
the EMBASE, Medline, Cochrane, and PubMed databases was 
performed. The primary keywords were Animals (newborn), 
Hypoxia, and Nitric Oxide Synthesis; the searches were limited 
to the English language. The complete search string is included 
in Supplementary Material. After the exclusion of duplicates, the 
titles and abstracts were independently screened by two research-
ers (Laurent M. A. Favié and Arlette R. Cox). A final selection was 
made after full text evaluation. Any discrepancies were resolved by 
a third researcher (Floris Groenendaal). In addition, the reference 
lists of the retrieved articles were searched for additional studies.
Selection Criteria
Studies were included based on the following inclusion criteria: 
animal models of a postnatal age in which brain development 
corresponds to near term or term brain development in humans, 
transient hypoxia or hypoxia–ischemia (HI), neuroprotection as 
outcome defined by histological, biochemical, and/or neurobe-
havioral parameters and inclusion of both a treatment group 
administering at least one NOS inhibitor and a control group 
that received sham treatment or consisted of untreated animals.
Data Synthesis
The year of publication, name of first author, the class and type 
of NOS inhibitor, the animal model, the method used to achieve 
HI, the dose and number of animals in each treatment group, the 
type of control group and number of control animals, the timing 
of administration with regards to the HI insult, and the results 
on the reported outcome parameters were recorded for each 
study. Each outcome parameter was categorized as histological, 
biochemical, or neurobehavioral.
Quality Assessment
The methodological quality of the included articles was assessed 
using the SYRCLE’s risk of bias (RoB) tool for animal intervention 
FigURe 1 | Study flow diagram. Abbreviations; n, number of studies; NOS, nitric oxide synthase.
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studies (33). This tool is based on the Cochrane RoB tool and 
consists of 10 items on which an article can be scored. Each 
item was scored 0, 1, or 2 points by two researchers (Laurent M. 
A. Favié and Arlette R. Cox) independently. If no evidence for 
adherence or evidence for non-adherence was found, a score of 
0 was awarded. When evidence for adherence was present but 
inconclusive, one point was scored. If the item was fully adhered 
to, two points were scored. Any discrepancies were resolved after 
consultation with a third researcher (Agnes van den Hoogen). 
Because of the nature of the included studies and the timing of the 
interventions, “allocation concealment” was deemed unfeasible 
and was not rated for any of the articles. Articles scoring 1–6 
points were considered low quality, 7–12 points moderate quality, 
and 13–18 points high quality. An example of the tool is included 
in Supplementary Material.
ReSULTS
eligible Studies
The search yielded a total of 348 studies; 280 studies after removal 
of duplicates. After screening of title and abstract, 238 articles 
were excluded. Screening of the reference lists identified one 
additional article. 43 articles were thus assessed in full detail. Of 
these, 26 were deemed eligible for inclusion (Figure 1); the data 
were extracted from these studies, and these studies were assessed 
for methodological quality. Performing a meta-analysis was con-
sidered impossible because of the heterogeneity of the studies in 
outcome, administered NOS inhibitor, and animal models.
Study Characteristics
The included studies and their descriptive characteristics are sum-
marized in Table 1. Eight studies (31%) tested a non-specific NOS 
inhibitor (34–41), another eight (31%) applied an nNOS-specific 
inhibitor (42–49); three studies (12%) used an iNOS-specific 
inhibitor (50–52); and six (23%) used an inhibitor of both nNOS 
and iNOS (53–58). One study (3%) used separate groups for 
nNOS and iNOS inhibition (59). Four different species of animals 
were used: rat (n = 11, 42%), piglet (n = 10, 38%), sheep (n = 3, 
12%), and rabbit (n = 2, 8%).
Different models for HI were used, mostly dependent on 
the animal species. All rat studies applied the Vannucci–Rice 
model in P7–P14 pups. All newborn (P1–P5) piglet studies 
induced brain injury by hypoxia for 30–60 min, in 30% of stud-
ies combined with transient bilateral artery occlusion. In sheep 
TABLe 1 | Study characteristics including RoB score.
First author 
(year)
nOS inhibitor 
class, type
Animal, age Hi method Dose, no., 
RoA
Control, no., 
RoA
Timing Outcome RoB L/M/H 
(score)
Parameter H/B/n, 
nP yes/no
Result
Trifiletti  
(1992) (34)
Non-spec, 
NNLA
Rat (Sprague-
Dawley), 7 days
Left carotid artery 
ligation and 
hypoxia (FiO2 
0.08) for unknown 
duration
50 mg/kg, 
n = 6, ip
Vehicle, n = 6, ip 15 h before 
insult
H, yes 89% reduction in ipsilateral/contralateral 
weight ratio disparity vs vehicle
L (3)
100 mg/kg, 
n = 4, ip
H, yes 100% reduction in ipsilateral/contralateral 
weight ratio disparity vs vehicle
Hamada 
(1994) (35)
Non-spec, 
NNLA
Rat (Wistar), 
7 days
Left carotid artery 
ligation and 
hypoxia (FiO2 0.08) 
for 150 min
2 mg/kg, 
n = 12, ip
Vehicle, n = 12, ip 90 min before 
insult
H, yes Reduction in cortical and striatal lesions 
vs vehicle
M (7)
2 mg/kg, 
n = 12, ip
Vehicle, n = 12, ip Directly after 
insult
H, no No reduction in cortical and striatal 
lesions vs vehicle
Nunagami 
(36)
Non-spec, 
NNLA
Piglet (unknown), 
2–4 days
Hypoxia (FiO2 
0.07) for 60 min
40 mg/kg, 
n = 5, iv
Vehicle, n = 5, iv 60 min before 
insult
B, yes Significant decrease in free radical 
formation of 65% vs vehicle
Preservation of Na–K–ATPase activity 
vs vehicle
Significant reduction in lipid peroxidation 
vs vehicle
M (7)
Groenendaal 
(1999) (37)
Non-spec, 
NNLA
Piglet (Yorkshire), 
1–3 days
Bilateral carotid 
artery occlusion 
and hypoxia (FiO2 
0.07) for 60 min
40 mg/kg, 
n = 5, iv
Vehicle, n = 5, iv 60 min before 
insult
B, no Worse cerebral energy status during and 
after HI vs vehicle (no change before HI)
L (6)
Ashraf  
(2002) (38) 
Non-spec, 
NNLA
Piglet (unknown), 
3–5 days
Hypoxia (FiO2 
0.05–0.15) for 
60 min
40 mg/kg, 
n = 6, NA
Untreated, n = 9, 
NA
Unknown time 
before insult
B, yes Prevention of hypoxia-induced 
upregulation of nitrated Bax protein vs 
untreated
L (5)
Zubrow 
(2002) (39)
Non-spec, 
NNLA
Piglet (Yorkshire), 
2–4 days
Hypoxia (FiO2 
0.07–0.09) for 
60 min
40 mg/kg, 
n = 7, iv
Vehicle, n = 6, iv 60 min before 
insult
B, yes Significant decrease in amount of Bax 
protein and DNA fragmentation vs 
vehicle
L (6)
Dorrepaal 
(1997) (40)
Non-spec, 
NNLA
Sheep (Romney/
Suffolk), 2–11 days
Hypoxia (FiO2 
0.06–0.08) for 
30 min followed 
by MABP < 35 
mmHG for 5 min
10 mg/kg, 
n = 6, iv
Vehicle, n = 6, iv Directly after 
insult
H, yes Non-significant lower brain–body mass 
ratio vs vehicle
Non-significant decrease in necrotic 
Purkinje cells vs vehicle
M (8)
B, yes Significant increase in cerebral metabolic 
oxygen rate vs vehicle
Significant recovery of electrocortical 
brain activity to baseline vs vehicle
40 mg/kg, 
n = 6, iv
H, yes Significant lower brain–body mass ratio 
vs vehicle
Non-significant decrease in necrotic 
Purkinje cells vs vehicle
B, yes Significant increase in cerebral metabolic 
oxygen rate vs vehicle
B, no No change in recovery of electrocortical 
brain activity to baseline vs vehicle
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First author 
(year)
nOS inhibitor 
class, type
Animal, age Hi method Dose, no., 
RoA
Control, no., 
RoA
Timing Outcome RoB L/M/H 
(score)
Parameter H/B/n, 
nP yes/no
Result
Blumberg 
(1991) (41)
Non-spec, 
l-NAME
Rat (Wistar), 
14 days
Right common 
artery ligation and 
hypoxia (FiO2 0.08) 
for 90 min
30 mg/kg, 
n = 16, ip
Vehicle, n = 18, ip Directly after 
insult
H, no No significant difference in size of 
infarction vs vehicle
M (8)
Ishida (2001) 
(42)
nNOS, 7-NI Rat (CD), 7 days Right common 
artery ligation and 
hypoxia (FiO2 0.08) 
for 120 min
50 mg/kg, 
n = NS, ip
Vehicle, n = NS, ip 30 min before 
insult
H, no No neuroprotection vs vehicle L (5)
100 mg/kg, 
n = NS, ip
30 min before 
insult
H, yes Significant reduction in the difference 
between the ipsilateral and contralateral 
cerebral hemisphere wet weights vs 
vehicle
50 mg/kg, 
n = NS, ip
15 min after 
insult
H, no No neuroprotection vs vehicle
100 mg/kg, 
n = NS, ip
15 min after 
insult
H, no No neuroprotection vs vehicle
Parikh (2003) 
(43)
nNOS, 7-NI Piglet (unknown), 
3–5 days
Hypoxia (FiO2 
0.05–0.07) for 
60 min
1 mg/kg, n = 6, 
ip
Untreated, n = 5, 
ip
Directly before 
insult
B, yes Less caspase-3 activity and less DNA 
fragmentation vs untreated
L (6)
Ashraf  
(2004) (44)
nNOS, 7-NI Piglet (Yorkshire), 
2–4 days
Hypoxia (FiO2 
0.05–0.15) for 
60 min
NA, n = 6, NA Untreated, n = 5, 
NA
Unknown time 
before insult
B, yes Prevention of hypoxia-induced decrease 
in protein tyrosine phosphatases activity 
vs untreated
L (5)
Yu (2011) 
(45)
nNOS, 7-NI Rabbit (New-
Zealand White), 
embryonic day 22 
(70% gestation)
Uterine ischemia 
for 40 min
0.1575 μmol/
kg, n = NS, iv
Vehicle, n = NS, iv 30 min before 
insult
N, yes Decrease in number of deaths vs vehicle
Significantly improved righting reflex vs 
vehicle
M (7)
nNOS, JI-8 0.1575 μmol/
kg, n = NS, iv
N, yes Significant increase in normal appearing 
kits vs vehicle; significant decrease in 
severely affected and dead kits vs vehicle
Significantly improved smell, muscle 
tone, and righting reflex vs vehicle
Overall better outcome vs 7-NI
Mishra  
(2006) (46)
nNOS, JI-10 Piglet (Yorkshire), 
3–5 days
Hypoxia (FiO2 
0.06) for 60 min
1 mg/kg, n = 5, 
ip
Untreated, n = 5, 
ip
Directly after 
insult
B, yes Decreased expression of Bax protein and 
DNA fragmentation vs untreated
L (6)
Drury  
(2013) (47)
nNOS, JI-10 Sheep (Romney/
Suffolk), GA 
103–104 
(term = 147 days)
Complete umbilical 
cord occlusion for 
25 min
0.044, n = 8, iv Vehicle, n = 8, iv 15 min before 
insult
H, yes Partial neuronal and white matter 
protection after 7 days recovery vs 
vehicle
M (10)
B, yes Delay in the onset of seizures on EEG 
vs vehicle
Drury  
(2014) (48)
nNOS, JI-10 Sheep (Romney/
Suffolk), GA 
103–104 
(term = 147 days)
Complete umbilical 
cord occlusion for 
25 min
0.022 mg/kg, 
n = 8, iv
Vehicle, n = 8, iv 30 min before 
insult
H, yes Significant reduction in loss of striatal 
phenotypic neurons vs vehicle
M (10)
5
Favié et al.
N
europrotection by N
O
S
 Inhibition
Frontiers in N
eurology | w
w
w
.frontiersin.org
A
pril 2018 | Volum
e 9 | A
rticle 258
(Continued )
TABLe 1 | Continued
First author 
(year)
nOS inhibitor 
class, type
Animal, age Hi method Dose, no., 
RoA
Control, no., 
RoA
Timing Outcome RoB L/M/H 
(score)
Parameter H/B/n, 
nP yes/no
Result
Ji  
(2009) (49)
nNOS, C5 
or C6
Rabbit (New-
Zealand White), 
embryonic day 22 
(70% gestation) 
Uterine ischemia 
for 40 min
NA, n = NS, iv Vehicle, n = NS, iv 30 min before 
insult
N, yes Less fetal/neonatal deaths vs vehicle
Less neurobehavioral abnormalities vs 
vehicle
More normal kits at P1 vs vehicle
L (5)
nNOS, C6 NA, n = NS, iv 30 min after 
insult
N, no No difference in fetal/neonatal deaths 
vs vehicle
No difference in neurobehavioral 
abnormalities vs vehicle
No difference in normal kits at P1 vs 
vehicle
Ikeno  
(2000) (50)
iNOS, S-MI Rat (Wistar), 
7 days
Right carotid 
artery ligation and 
hypoxia (FiO2 0.08) 
for 90 min
10 mg/kg, 
n = NS, ip
Vehicle, n = NS, ip Directly before 
insult, repeated 
at 12, 24, 36, 
and 48 h
H, yes Significantly decreased damage to the 
cerebral cortex vs vehicle
L (5)
Tsuji  
(2000) (51)
iNOS, AG Rat (Wistar), 
7 days
Left carotid artery 
ligation and 
hypoxia (FiO2 0.08) 
for 150 min
300 mg/kg, 
n = 29, ip
Vehicle, n = 24, ip 60 min before 
insult, repeated 
every 8 h, nine 
doses in total
H, yes Significant reduction in cortical infarct 
volume of 89% vs vehicle
Significant reduction in striatal infarct 
volume of 90% vs vehicle
M (8)
Tutak  
(2005) (52)
iNOS, AG Rat (Wistar), 
7 days
Left carotid 
artery ligation 
and hypoxia for 
150 min
300 mg/kg, 
n = 18, ip
Vehicle, n = 18, 
30 min after insult, 
repeated every 
12 h, ip
30 min after 
insult, repeated 
every 12 h, six 
doses in total
H, no No reduction in mean infarcted area vs 
vehicle
M (12)
iNOS, IMC 0.2 mg/kg, 
n = 20, ip
30 min after 
insult, repeated 
every 8 h, nine 
doses in total
H, no No reduction in mean infarcted area vs 
vehicle
iNOS, AG and 
IMC
300 and 
0.2 mg/kg, 
n = 18, ip
AG: 60 m 
before insult; 
IMC: 30 m after 
insult, repeated 
every 8 h, nine 
doses in total
H, yes Significant reduction in mean infarcted 
area vs vehicle
van den 
Tweel (2005) 
(53)
nNOS and 
iNOS, 2-IB
Rat (Wistar), 
12 days
Right carotid 
artery ligation and 
hypoxia (FiO2 0.08) 
for 90 min
5.5 mg/kg, 
n = 11, sc
Vehicle, n = 24, 
sc
Directly after 
insult, repeated 
at 12 and 24 h
H, no No difference in hippocampus and cortex 
neuropathology score vs vehicle
No difference in ipsilateral/contralateral 
hemisphere area ratio vs vehicle
M (8)
10 mg/kg, 
n = 10, sc
H, yes Significantly higher hippocampus and 
cortex neuropathology score vs vehicle30 mg/kg, 
n = 20, sc H, no No difference in ipsilateral/contralateral 
hemisphere area ratio vs vehicle
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TABLe 1 | Continued
(Continued )
First author 
(year)
nOS inhibitor 
class, type
Animal, age Hi method Dose, no., 
RoA
Control, no., 
RoA
Timing Outcome RoB L/M/H 
(score)
Parameter H/B/n, 
nP yes/no
Result
B, yes Significantly higher hippocampus and 
cortex neuropathology score vs vehicle
Significantly higher ipsilateral/
contralateral hemisphere area ratio vs 
vehicle
B, yes Significantly lower ipsilateral HSP70 level 
vs vehicle
H, no No difference in nitrotyrosine levels vs 
vehicle
Nijboer 
(2007) (54)
nNOS and 
iNOS, 2-IB
Rat (Wistar), 
7 days
Right carotid 
artery ligation and 
hypoxia (FiO2 0.08) 
for 120 min
10 mg/kg, 
n = NS, sc
Vehicle, n = NS, 
sc
Directly after 
insult, repeated 
at 12 and 24 h
H, yes Significantly higher ipsilateral/
contralateral hippocampus area ratio vs 
vehicle in females only
Significant reduction in cortical and 
hippocampal lesions vs vehicle in 
females only
M (11)
B, yes Significant reduction in cytochrome c 
release vs vehicle in females only
Decrease in caspase-3 activity vs vehicle 
in females only
No effect on nuclear translocation of 
apoptosis-inducing factor vs vehicle in 
both genders
N, yes Less deaths in female pups compared 
with male pups
Peeters-
Scholte 
(2002) (55)
nNOS and 
iNOS, 2-IB
Piglet (Dutch 
Store) 1–3 days
Bilateral carotid 
artery occlusion 
and hypoxia for 
60 min
0.2 mg/kg, 
n = 11, iv
Vehicle, n = 12, iv Directly after 
insult, repeated 
every 60 min, 
six doses in 
total
H, yes 90% reduction of vascular edema vs 
vehicle
60–80% increase in normal neuronal 
cells vs vehicle
M (7)
B, yes 90% improvement of cerebral energy 
state vs vehicle
Reduction of caspase-3 activity by  
93% in cortex and 71% in striatum  
vs vehicle
Peeters-
Scholte 
(2002) (56)
nNOS and 
iNOS, 2-IB
Piglet (Dutch 
Store) 1–3 days
Bilateral carotid 
artery occlusion 
and hypoxia for 
60 min
0.2 mg/kg, 
n = 11, iv
Vehicle, n = 12, iv Directly after 
insult, repeated 
every 60 min, 
six doses in 
total
B, yes Preservation of endogenous IGF-1 
production vs vehicle
Reduction of caspase-3 activity vs 
vehicle
L (4)
B, no No significant decrease in cytokine 
production vs vehicle
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TABLe 1 | Continued
(Continued )
First author 
(year)
nOS inhibitor 
class, type
Animal, age Hi method Dose, no., 
RoA
Control, no., 
RoA
Timing Outcome RoB L/M/H 
(score)
Parameter H/B/n, 
nP yes/no
Result
Bjorkman 
(2013) (57)
nNOS and 
iNOS, 2-IB
Piglet (Yorkshire), 
newborn
Hypoxia (FiO2 
0.02–0.04) for 
30 min
0.1 mg/kg, 
n = 7, iv
Vehicle, n = 10, iv Directly after 
insult, repeated 
every 60 min, 
six doses in 
total
H, yes Decreased nitration in thalamus, parietal 
and temporal cortex vs vehicle
M (11)
H, no No difference in neuronal injury histology 
score
B, no No difference in electrographical seizure 
activity at 48 h vs vehicle
No difference in caspase-3 activity vs 
vehicle
N, yes Increased survival with normal EEG at 
48 h vs vehicle
N, no No difference in neurobehavioral scores 
at 48 h vs vehicle
0.2 mg/kg, 
n = 9, iv
H, yes Decreased nitration in thalamus, parietal 
and temporal cortex vs vehicle
H, no No difference in neuronal injury histology 
score
B, yes Lower electrographical seizure activity at 
48 h vs vehicle
B, no No difference in Caspase-3 activity vs 
vehicle
N, yes Increased survival with normal EEG at 
48 h vs vehicle
N, no No difference in neurobehavioral scores 
at 48 h vs vehicle
1.0 mg/kg, 
n = 5, iv
H, yes Decreased nitration in thalamus, parietal 
and temporal cortex vs vehicle
H, no No difference in neuronal injury histology 
score
B, yes Lower electrographical seizure activity at 
48 h vs vehicle
B, no No difference in caspase-3 activity vs 
vehicle
N, yes Increased survival with normal EEG at 
48 h vs vehicle
N, no No difference in neurobehavioral scores 
at 48 h vs vehicle
van den 
Tweel (2002) 
(58)
nNOS and 
iNOS, 7-NI and 
AG
Rat (Sprague-
Dawley), 12 days
Right carotid 
artery ligation and 
hypoxia (FiO2 0.08) 
for 90 min
50 and 100 mg/
kg, n = 24, ip
Vehicle, n = 24, ip Directly after 
insult, AG 
repeated every 
12 h, four 
doses in total
H, yes Significant reduction in brain damage to 
the ipsilateral hemisphere vs vehicle
M (12)
B, no No difference in HSP70 or cytokine 
mRNA expression vs vehicle
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(Continued )
First author 
(year)
nOS inhibitor 
class, type
Animal, age Hi method Dose, no., 
RoA
Control, no., 
RoA
Timing Outcome RoB L/M/H 
(score)
Parameter H/B/n, 
nP yes/no
Result
Hsu (2014) 
(59)
nNOS, 7-NI Rat (Sprague-
Dawley), 7 days
Right carotid 
artery ligation and 
hypoxia (FiO2 0.08) 
for 120 min
75 mg/kg, 
n = NS, ip
Vehicle, n = NS, ip 30 min before 
insult
H, yes Higher ipsilateral/contralateral cortical 
area ratio vs vehicle and AG
Significant increases in vascular density 
and decreases of BBB damage and 
microglia activation vs vehicle
Decrease in microvascular nitrosative 
stress vs vehicle and AG
M (7)
B, yes Increased cerebral perfusion vs vehicle 
and AG
3 h after insult H, no No difference in ipsilateral/contralateral 
cortical area ratio vs vehicle
iNOS, AG 300 mg/kg, 
n = NS, ip
30 min before 
insult
H, yes Higher ipsilateral/contralateral cortical 
area ratio vs vehicle
Significant increases in vascular density 
and decreases of BBB damage and 
microglia activation vs vehicle
H, no No change in microvascular nitrosative 
stress vs vehicle
B, no No change in cerebral perfusion vs 
vehicle
3 h after insult H, yes Higher ipsilateral/contralateral cortical 
area ratio vs vehicle and 7-NI
Studies are grouped by class and type of NOS inhibitor and subsequently by type of animal tested and year of publication. Low quality studies are indicated by a gray background.
non-spec, non-specific; NNLA, N-nitro-l-arginine; l-NAME, N-nitro-l-arginine methyl ester; nNOS, neuronal nitric oxide synthase; 7-NI, 7-nitro indazole; iNOS, inducible nitric oxide synthase; S-MI, S-methyl-isothiourea; AG, 
aminoguanidine; IMC, indomethacin; 2-IB, 2-iminobiotin; GA, gestational age; FiO2, fraction of inspired oxygen; MABP, mean arterial blood pressure; RoA, route of administration; ip, intraperitoneal; iv, intravenous; sc, subcutaneous; 
NP, neuroprotection; H, histological; B, biochemical; N, neurobehavioral; HI, hypoxia–ischemia; HSP70, heat shock protein 70; EEG, electro-encephalogram; BBB, blood–brain barrier; RoB, risk of bias; L, low; M, moderate; NA, not 
available; NOS, nitric oxide synthase; NS, not specified.
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aged 2–11 days (one study), hypoxia for 30 min was combined 
with hypotension for 5  min. Also, two studies using sheep at 
103–104  days gestation (term =  147  days) were included, in 
which brain injury was induced by hypoxia due to occlusion 
of the umbilical cord for 25 min. In rabbits, fetuses (embryonic 
day 22, 70% gestation) were subjected to an HI event by uterine 
ischemia for 40 min.
The dosing regimen of the included studies is summarized 
in Table  2. Seventeen studies (65%, all non-specific or nNOS-
specific inhibitors) describe only a single administration, and 
nine studies (35%, all iNOS of combined nNOS and iNOS 
inhibitors) described repeated dosing. With regards to timing of 
the intervention, 12 studies (46%) administered the (first) dose 
before the onset of the HI event; 9 (35%) after the event; and the 
remaining 5 (19%) incorporated groups with administration both 
before and after the event.
Outcome
The results of the reported outcome parameters for each study are 
presented in Table 1. A wide variety of histological, biochemi-
cal, and neurobehavioral outcome parameters were reported. 
Histological parameters included ipsilateral/contralateral weight 
ratio disparity and analysis of cortical and striatal lesions. 
Biochemical parameters included free radical formation and 
other biomarkers for neurological damage, but also cerebral 
energy status and electrocortical brain activity. Neurobehavioral 
parameters included overall survival, survival with normal EEG 
and results of neurobehavioral tests.
In the group of non-specific NOS inhibitors, administration 
before onset of the insult proved neuroprotective in 7/8 settings 
(88%), while administration directly after the insult was partially 
beneficial in 2/3 settings (67%).
For nNOS inhibitors, administration before the insult showed 
neuroprotective properties in 9/10 settings (90%) and when 
administered directly after the insult (1/1). When administration 
was delayed by 15 min or more, neuroprotective properties were 
lost (4/4).
When treatment with an iNOS inhibitor was started before 
the insult, neuroprotection was achieved (4/4). Administering 
the first dose after induction of HI showed neuroprotection in 
33% of the settings (1/3). Hsu et al. administered the iNOS inhibi-
tor aminoguanidine (AG) 30 min before and 3 h after the insult 
as a single dose. Both were neuroprotective compared with the 
control group, although less parameters were tested in the post 
insult treatment group.
All studies testing combined inhibition of nNOS and iNOS 
reported (partially) neuroprotective outcome. van den Tweel 
et al. (53) showed that 2-iminobiotin (2-IB) is neuroprotective in 
rats in a dose-dependent matter.
A direct comparison between two different inhibitors was 
made in two studies. Yu et al. reported superior neuroprotection 
of the novel nNOS inhibitor JI-8 compared with 7-nitro indazole 
(7-NI) when administered before the insult in equimolar doses. 
Hsu et al. observed that both 7-NI and AG are neuroprotective 
when administered 30 min before HI and that 7-NI is superior to 
AG in this setting. When the compounds were administered 3 h 
after HI, 7-NI lost its neuroprotective effect while AG remained 
neuroprotective compared with both vehicle and 7-NI.
Methodological Quality
Eleven studies (42%) were ranked low quality, 15 (58%) were con-
sidered moderate quality; none of the studies were ranked in the 
high quality group. On average, RoB score was 7 (3–12). Overall, 
animal baseline characteristics, randomization for treatment 
allocation, blinding of investigators and/or outcome assessors, 
and random selection for outcome assessment were often not 
mentioned and therefore scored 0.
DiSCUSSiOn
This systematic review shows that both selective and non-selective 
NOS inhibitors have neuroprotective qualities in various animal 
models of HI brain damage using histological, biochemical, 
and neurobehavioral outcome parameters. In animal studies, 
induction of the insult and administration of the potentially neu-
roprotective agent (before and/or after the insult) can be timed 
precisely. By contrast, this is not the case in clinical practice. The 
onset of perinatal asphyxia is often sudden and unpredictable. 
Therefore, administration of any drug before the onset of the 
insult is impossible, and administration directly after the insult 
(i.e., directly after birth) is highly improbable. All non-selective 
NOS inhibitors reviewed in this study were administered before 
insult or directly after; there are no data on delayed administra-
tion. Furthermore, non-selective inhibitors will also target eNOS, 
which could counteract the potential neuroprotective effects of 
TABLe 2 | Dosing frequency and timing of intervention for the included studies.
Timing of first dose to Hi event Dosing frequency Type of inhibitor Total no of 
studies
non-specific nnOS inOS nnOS + inOS
Prior Single 5 5 – – 10 12
Repeated – – 2 – 2
Post Single 2 1 – – 3 9
Repeated – – – 6 6
Both Single 1 3a 1a – 4a 5a
Repeated – – 1 – 1
Total 8 9 4 6 26
aOne study tested both an nNOS and iNOS inhibitior in separate groups.
non-spec, non-specific; nNOS, neuronal nitric oxide synthase; iNOS, inducible nitric oxide synthase; HI, hypoxia–ischemia.
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nNOS and iNOS inhibition. For selective nNOS inhibitors, neu-
roprotection was lost when administration was withheld by as lit-
tle as 15 min. For selective iNOS inhibitors, administration before 
the insult shows greater neuroprotective potential than post-
insult treatment. The combination of nNOS and iNOS inhibition 
shows neuroprotective properties on histological, biochemical, 
and neurobehavioral outcome parameters when administered 
after the insult in a repeated dosing regimen. Thus, combined 
nNOS/iNOS inhibition with a repeated dosing regimen seems the 
most promising strategy to advance into human clinical trials. In 
fact, several phase II studies with 2-IB are currently underway, in 
addition to TH (NTR5221) as well as without TH in low-income 
countries (NCT01626924, EudraCT2015-003063-12).
Because of the wide variety in reported outcome measures, a 
clear-cut comparison between inhibitors based on outcome was 
difficult to make. Twelve studies report no neuroprotection on one 
or more outcome parameters after NOS inhibition. Potentially, 
this can be attributed to timing of the intervention or suboptimal 
dosing. When a NOS inhibitor is administered before the insult, 
the compound will be present in the tissues and circulation at 
the time of the actual insult, increasing the compound’s potential 
to exhibit neuroprotective effects. Most studies have tested one 
NOS inhibitor in a single dose. In studies testing different dos-
ages, a higher dose often shows a better neuroprotective outcome, 
although some studies indicate a U-shaped effect. For 2-IB, the 
optimal dose in rats appears to be 30  mg/kg intraperitoneal 
(53). In piglets, increasing the dose by five times to 1.0  mg/kg 
intravenous does not provide greater neuroprotective properties 
compared with 0.2 mg/kg (57). Although most studies measured 
histological and biochemical outcome parameters associated 
with neuroprotection, the clinically most relevant parameter of 
improved neurobehavioral outcome was reported in four studies 
only. Yu et al. (45) and Ji et al. (49) showed that nNOS inhibition 
administered before the insult resulted in less deaths, and less 
neurobehavioral abnormalities in rabbits. Nijboer et al. (54) and 
Bjorkman et al. (57) report a (partial) neuroprotective effect for 
2-IB on neurobehavioral outcome parameters in rats and piglets, 
respectively. Assessing neurobehavioral outcome requires a 
longer follow up period, which often involves intensive hands-on 
trained personnel especially in larger animal models, as well as 
validated tools to score the desired outcome parameter, making 
it very expensive. Using histological and biochemical markers 
provides researchers with a more time- and cost-effective alterna-
tive. Although data are limited, results on neurobehavioral out-
come parameters, combined with results from histological and 
biochemical parameters, identify NOS inhibition as a potential 
neuroprotective strategy in humans.
Important differences exist between the adult and the neonatal 
brain with regard to susceptibility to injury, plasticity and cell 
death pathways. Therefore, adult animal models are not suitable 
to examine neuroprotective interventions for HIE. Across spe-
cies, key brain maturation events regarding susceptibility and 
regenerative capacities have been identified at different moments 
before and after birth and are related to the developmental stage 
of the human neonatal brain (60–62). It is generally accepted that 
rats, at postnatal days 7–14 (P7–14), are comparable to near term/
term human neonates with regards to cerebral cortex development 
(63, 64). The Vannucci–Rice model of unilateral common carotid 
artery ligation followed by a period of systemic hypoxia results 
in apoptotic-necrotic cell degeneration in P7–14 rats, similar to 
HIE (64–67). In term piglets aged 1–5 days, hypoxia leads to basal 
ganglia and somatosensory cortical injury, largely comparable to 
damage seen in human neonates after perinatal asphyxia (64, 
68, 69). Introducing HI in utero to fetal rabbits provides animals 
with a motor phenotype similar to human cerebral palsy (64, 70). 
In term and preterm sheep models, hypoxia and asphyxia cause 
abnormalities in cerebral oxygen metabolism and hemodynamics 
as well as electrocortical brain activity comparable to human neo-
nates after HI and basal ganglia injury representative for cerebral 
palsy (71–73).
Of interest is the potential role of sex-specific cell death path-
ways involved in HIE and possible sex-specific neuroprotective 
therapies. In general, females seem to be less susceptible to brain 
injury. This effect is seen across species, age groups, and origin of 
injury (74). In adult animal models, reduction in ischemic injury 
in females has been attributed to estradiol levels (74). Although 
estradiol will not be as predominant in prepubertal animal mod-
els, there is evidence of sexual dimorphism regarding sex steroids 
in central nervous system development in mice and rats (75, 76). 
Other studies show sex-specific cell death pathways leading to 
brain injury after HI both in vitro and in vivo. For instance, there is 
evidence that brain injury after HI in males is evoked by caspase-
independent pathways whereas in females, caspase-dependent 
pathways are responsible (77–82). Therefore, neuroprotective 
agents such as NOS inhibitors that interact, either upstream or 
downstream, with the caspase-dependent pathway may be effec-
tive in females only.
The role of sex was only sparsely investigated in the studies 
included. For the majority of the studies (65%), the sex of the 
animals used was not reported. Six studies (23%) used rats of 
both sexes but have not reported sex-specific outcome. Yu et al. 
reported no outcome differences between sex for 7-NI and JI-9 
but this statement was not supported by statistical analysis, 
possibly due to the small sample size in each of the groups (45). 
Nijboer et al. showed a statistically significant difference in his-
tological and biochemical outcome parameters between sexes in 
rats, concluding that 2-IB was neuroprotective in female rats only 
(54). Other studies with different neuroprotective agents in both 
animals and humans also indicate a (potential) neuroprotective 
effect in females only (81–84).
Methodological quality assessment using the SYRCLE’s RoB 
tool resulted in only low and moderate scores for the publications 
used in this study. In all of the studies, at least on one or more items 
no information was available, forcing a score of 0 in that area. It 
is unknown whether these items were not adhered to during the 
experiment, or simply not included in the final manuscript due to 
regulations imposed by the editorial guidelines of the publishing 
journal. Unfortunately, it is not yet common practice to be as 
complete and precise in reporting data for animal studies as it 
is for human studies (33, 85). However, since this problem was 
addressed in a commentary published in the Lancet in 2002, 
awareness has been steadily increasing (86, 87). Fourteen of the 
studies included in this review were published in or before 2002; 
seven (50%) scoring low and an equal number scoring moderate. 
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